{"subject": "CHEBI:28748", "predicate": "biolink:affects", "object": "NCBIGene:7515", "primary_knowledge_source": "infores:text-mining-provider-targeted", "publications": ["PMID:28258155", "PMID:29929045", "PMID:34783124"], "tmkp_confidence_score": 0.9983171550000001, "sentences": "The significant increase in CDKN1A and XRCC1 suggest a cell cycle arrest and implies an alternative NHEJ pathway in response to doxorubicin-induced DNA breaks.|NA|However, FANCD2, BRCA1 and XRCC1 foci, prominently associated with 53BP1 foci and hence DSBs resolved by cNHEJ, were only detected in doxorubicin-treated XRCC4-deficient cells.|NA", "tmkp_ids": ["tmkp:0792c702bebbc0eea6d08d4c1b4911679ae23b03775b11345d868db6cf670fe4", "tmkp:551578d2b184d7e406e3b2f81a800c880fe80a93283abbbe55e8573c2228687a", "tmkp:5fd679cb1d20061fa8cbc5fab5f65c1581afd2e6436cef845ca4f2a7f95e353f", "tmkp:ae3877b6ed48c7afbc0991e8578f84513dd12cacb2bb6a485df182d33d4d4e7f", "tmkp:bb27255bd16ceeab7135e5b967f5a9b28fd98024c4152a494c6c341dec11bf01"], "knowledge_level": "not_provided", "agent_type": "text_mining_agent", "qualified_predicate": "biolink:causes", "object_aspect_qualifier": "activity_or_abundance", "object_direction_qualifier": "increased", "original_subject": "CHEBI:28748", "original_object": "UniProtKB:P18887"}
{"subject": "UMLS:C0733758", "predicate": "biolink:affects", "object": "NCBIGene:8788", "primary_knowledge_source": "infores:text-mining-provider-targeted", "publications": ["PMC:9308958", "PMC:9308958", "PMC:9308958"], "tmkp_confidence_score": 0.9913376566666666, "sentences": "In our invitro approach FSH furthermore directly upregulated expression of the non-canonical Notch ligand DLK1 establishing a link between FSH/FSHR and DLK1 that, to our knowledge, has not been reported previously.|NA|(D) FSH stimulation for 8?h on Day 8 of differentiation reduced FSHR expression and increased expression of Inhibin ? subunit (INHA), Steroidogenic Acute Regulatory Protein (StAR) and Delta Like Non-Canonical Notch Ligand (DLK1) in WT cells (black bars) but not in A189V mutant lines (light and dark gray bars).|NA|The expression of steroidogenic acute regulatory protein (StAR) and delta like non-canonical notch ligand 1 (DLK1) were also stimulated by FSH and forskolin (Fig.?1D) [FSH stimulations ANOVA, Bonferroni test, P (StAR, FSH 10?ng/ml) = 0.068, P (StAR, FSH 100?ng/ml) = 4.6E?05, P (DLK1, FSH 10?ng/ml) = 0.754, P (DLK1, FSH 100?ng/ml) = 0.002, forskolin t-test, adjusted P (StAR) = 1.34E?08,|NA", "tmkp_ids": ["tmkp:91b3c883a4bfff31749e96cf07c54b645c8970e00b1e0d51375f3507326bd3b2", "tmkp:f412ff05026d6c987d53c91ff00142a953eaaea2206e691ddbb8840652675631", "tmkp:e830a6e9dd99c46741c73a3c5e65150e000385d3d2491851354aea613a213a82"], "knowledge_level": "not_provided", "agent_type": "text_mining_agent", "qualified_predicate": "biolink:causes", "object_aspect_qualifier": "activity_or_abundance", "object_direction_qualifier": "increased", "original_subject": "DRUGBANK:DB00066", "original_object": "UniProtKB:P80370"}
{"subject": "UMLS:C3896731", "predicate": "biolink:treats_or_applied_or_studied_to_treat", "object": "MONDO:0018874", "primary_knowledge_source": "infores:text-mining-provider-targeted", "publications": ["PMC:5767051", "PMC:7789799", "PMC:8470441", "PMC:8537004", "PMC:8582601", "PMC:8649641", "PMC:8749975", "PMC:9146966"], "tmkp_confidence_score": 0.9062430810801192, "sentences": "In a phase I/II clinical study (NCT02152956), patients with primary induction failure (PIF) or early relapsed (ER) AML received flotetuzumab monotherapy.|NA|Flotetuzumab for the Treatment of Pediatric Recurrent or Refractory Acute Myeloid Leukemia|NA|Flotetuzumab, another DART that binds CD3 and CD123, is currently being studied in a phase I clinical trial in patients with relapsed or refractory acute myeloid leukemia (AML) and intermediate/high-risk myelodysplastic syndrome (MDS) (NCT02152956).|NA|CRS was observed in all AML patients treated with Flotetuzumab and 58% of AML patients treated with Vibecotamab (XmAb14045), another CD3xCD123 BiAb.|NA|Anti-CD123 targeted immunotherapies (e.g., IMGN-632, flotetuzumab) have shown promising activity in preclinical models of acute myeloid leukemia (AML) and are under current clinical investigation in early-phase trials for patients with relapsed/refractory AML.|NA", "tmkp_ids": ["tmkp:0ddc6b4ff3aa20320a8f482c7838cfe264703c133ec628f485c56b939a5db29f", "tmkp:0e5a620b980c332b613fc8ceaf2ed7e857f16ff6eedae9bcfd6a8162c66f37b1", "tmkp:4d63d3a050e2bfb5d9772f7e5f4d1c6e380e28831e399b0f6be1e39acac522ba", "tmkp:6f137fb4cf08ce6229ca22c41f4230de8d0c7865e4d13b3ea83562ca7a84ff52", "tmkp:739248eaefe6faedc9de66c46d5bb61b2c036242be46a6d8e5dd21f9e1e11667", "tmkp:8025446698f27df311ceb61ba143f55d6fa3b910546335d467f70a407c67cbb2", "tmkp:bf5b8934ba854e1c6c329caa7359b4c5e2613a195c140b3f2b0d571d95d61d8e", "tmkp:fe6bc6720edd353932f568c8efc2e0f34ea89fef18207a061414eb573eb8d95f"], "knowledge_level": "not_provided", "agent_type": "text_mining_agent", "original_subject": "DRUGBANK:DB15223", "original_object": "MONDO:0018874"}
{"subject": "UNII:5L3SX16QBQ", "predicate": "biolink:treats_or_applied_or_studied_to_treat", "object": "MONDO:0004979", "primary_knowledge_source": "infores:text-mining-provider-targeted", "publications": ["PMC:8692160", "PMC:9003539", "PMC:7652256", "PMC:7050994"], "tmkp_confidence_score": 0.9007020194955808, "sentences": "Discovery of 6-Amino-2-{[(1S)-1-methylbutyl]oxy}-9-[5-(1-piperidinyl)pentyl]-7,9-dihydro-8H-purin-8-one (GSK2245035), a Highly Potent and Selective Intranasal Toll-Like Receptor 7 Agonist for the Treatment of Asthma|NA|Discovery of 6-Amino-2-{[(1S)-1-methylbutyl]oxy}-9-[5-(1-piperidinyl)pentyl]-7,9-dihydro-8H-purin-8-one (GSK2245035), a Highly Potent and Selective Intranasal Toll-Like Receptor 7 Agonist for the Treatment of Asthma|NA|Steroid-naive participants with mild asthma who demonstrated an early and late asthmatic response when challenged with one of four common perennial or seasonal inhaled aeroallergens (cat dander, birch pollen, house dust mite, or grass-mix) were administered intranasal GSK2245035 20 ng or placebo once weekly for 8 weeks.|NA|Discovery of 6-Amino-2-{[(1S)-1-methylbutyl]oxy}?9-[5-(1-piperidinyl)pentyl]-7,9-dihydro-8H-purin-8-one e (GSK2245035), a highly potent and selective intranasal toll-like receptor 7 agonist for the treatment of asthma     |NA", "tmkp_ids": ["tmkp:7deb7f39b82e6e2b7f4dd23824d42b072513ebd2a559a66246f59a097b093a63", "tmkp:a8279ae370c7f77d498cef12a6b2bf788aa75af1c8a7015e90972331181d20be", "tmkp:e3654b3a2e7e3ea71a89856a770edf077fa821ff0b6003944b3968958de81967", "tmkp:c4ece597e17769922b5df7bfdb38a45ae19fca5df0e08438f2d7a09e78c426a9"], "knowledge_level": "not_provided", "agent_type": "text_mining_agent", "original_subject": "DRUGBANK:DB16076", "original_object": "MONDO:0004979"}
{"subject": "NCBIGene:351", "predicate": "biolink:affects", "object": "NCBIGene:2890", "primary_knowledge_source": "infores:text-mining-provider-targeted", "publications": ["PMC:7476873", "PMC:7476873"], "tmkp_confidence_score": 0.9513757249999999, "sentences": "In APP/PS1 mice injected with either GFP-GluA1-WT or GFP-GluA1-4KQ, we found a specific increase in GluA1 in both the hippocampus (Figures 5F and 5G) and, to a lesser extent, in the cortex (Figures S1A and S1B) compared with APP/PS1 controls.|NA|In APP/PS1 mice injected with either GFP-GluA1-WT or GFP-GluA1-4KQ, we found a specific increase in GluA1 in both the hippocampus (Figures 5F and 5G) and, to a lesser extent, in the cortex (Figures S1A and S1B) compared with APP/PS1 controls.|NA", "tmkp_ids": ["tmkp:3688bb3077ec93168ad862780642febd79ee1c71d6cec82b29da296559e47d24", "tmkp:41a205e3eb1ede0878ee0c2112145fdaae890c7b8bbb3628e81e0602cbbbf8ba"], "knowledge_level": "not_provided", "agent_type": "text_mining_agent", "qualified_predicate": "biolink:causes", "object_aspect_qualifier": "activity_or_abundance", "object_direction_qualifier": "increased", "original_subject": "UniProtKB:P05067", "original_object": "UniProtKB:P42261"}
{"subject": "CHEBI:30812", "predicate": "biolink:contributes_to", "object": "MONDO:0005559", "primary_knowledge_source": "infores:text-mining-provider-targeted", "publications": ["PMC:7747873"], "tmkp_confidence_score": 1.240363873664695, "sentences": "Furthermore, in the model of cortical injection of ferrous chloride, neurodegeneration is limited to the cortex.|NA", "tmkp_ids": ["tmkp:152341005c16f9080cde8c31134f64a87c0b2da4aca9f058704014a59e73ad5f"], "knowledge_level": "not_provided", "agent_type": "text_mining_agent", "original_subject": "DRUGBANK:DB13569", "original_object": "HP:0002180"}
{"subject": "CHEBI:17650", "predicate": "biolink:treats_or_applied_or_studied_to_treat", "object": "MONDO:0003709", "primary_knowledge_source": "infores:text-mining-provider-targeted", "publications": ["PMC:8978549"], "tmkp_confidence_score": 0.99826247, "sentences": "For instance, observed that such higher cortisol levels during therapeutic exposures for panic disorder and agoraphobia were associated with lower avoidance behavior, lower threat appraisal, and higher perceived control throughout and at the end of treatment.|NA", "tmkp_ids": ["tmkp:5d43fbabb076c9e5607ec43b54012610364926639f6ba425a2dbf72ccf246e49", "tmkp:a832b822bf29cfe6622b2dfa6cda9eec8e42bd7480504287dc549ea1cb3d140f"], "knowledge_level": "not_provided", "agent_type": "text_mining_agent", "original_subject": "CHEBI:17650", "original_object": "MONDO:0003709"}
{"subject": "CHEBI:37758", "predicate": "biolink:contributes_to", "object": "HP:0001945", "primary_knowledge_source": "infores:text-mining-provider-targeted", "publications": ["PMC:8570226"], "tmkp_confidence_score": 0.83672262923918, "sentences": "Similar to bismuth, iodoform and iodine toxicity manifests with neuropsychiatric symptoms of malaise, decreased appetite, headache, agitation, depression or delirium, drowsiness and semi-coma, gastrointestinal symptoms of nausea and vomiting, and constitutional symptoms such as fever and tachycardia.|NA", "tmkp_ids": ["tmkp:03efebc69131dcf90a6398b8b13813d82338a6ecca67fe07a4e5b544815913e1"], "knowledge_level": "not_provided", "agent_type": "text_mining_agent", "original_subject": "DRUGBANK:DB13813", "original_object": "HP:0001945"}
{"subject": "CHEBI:2682", "predicate": "biolink:contributes_to", "object": "MONDO:0005560", "primary_knowledge_source": "infores:text-mining-provider-targeted", "publications": ["PMC:7091772"], "tmkp_confidence_score": 0.7744422484188938, "sentences": "Encephalopathy was attributed to Amphotericin B or Cyclosporine when a compatible MRI picture was seen, other diagnostic possibilities were excluded, and/or resolution of symptoms was seen after withdrawal of the medication.|NA", "tmkp_ids": ["tmkp:3734a41505069984c15358e2f14aae24c75444b0d352c0f5d0593b8537693f75"], "knowledge_level": "not_provided", "agent_type": "text_mining_agent", "original_subject": "DRUGBANK:DB00681", "original_object": "HP:0001298"}
{"subject": "CHEBI:9332", "predicate": "biolink:treats_or_applied_or_studied_to_treat", "object": "HP:0000010", "primary_knowledge_source": "infores:text-mining-provider-targeted", "publications": ["PMC:6556801", "PMC:7430156", "PMC:4887100", "PMC:6903708", "PMC:7779487"], "tmkp_confidence_score": 0.999518288, "sentences": "Additionally, chloramphenicol and trimethoprim/sulfamethoxazole are also common choices for treatment of UTI and diarrhea associated with E. coli in humans and animals.|NA|Sulfamethoxazole (SMZ or SMX), another FDA-approved ligand, is an antibiotic used for bacterial infections such as urinary tract infections, bronchitis, and prostatitis.|NA|UPEC within IBCs are protected from both phagocytosis by PMNs and many antibiotics, particularly the first-line drug trimethoprim-sulfamethoxazole, which has increased efficacy against UTI because it concentrates in the urine but is relatively cell-impermeant.|NA|Urinary tract infections (UTIs) caused by Escherichia coli have been historically managed with oral antibiotics including the cephalosporins, fluoroquinolones and trimethoprim-sulfamethoxazole.|NA|Trimethoprim-sulfamethoxazole (TMP-SMX) was the preferred antibiotic for UTI treatment for many years due to its efficacy and low cost.|NA", "tmkp_ids": ["tmkp:81d75d641f9db1bcdadeb7c29dd014c0fc8595571b0506043d890fbdf83fef83", "tmkp:01757ae45cbffa67779682d35917ed235e14f0356045c2ae081dde8911dca4a0", "tmkp:9e70772947ff13767f0a77d73eca87d07dea2d6bea4960b04a2e81ea6a8075f1", "tmkp:af9b01ace3280a44624fe65adf859027c34eb9827ada4fb0ff16cc22ddde36a5", "tmkp:723c9f4ff52d3c789641cd4ab734eb9786a072d33332b83f7e2031c8176a1a07"], "knowledge_level": "not_provided", "agent_type": "text_mining_agent", "original_subject": "DRUGBANK:DB01015", "original_object": "HP:0000010"}
{"subject": "CHEBI:6890", "predicate": "biolink:affects", "object": "NCBIGene:5581", "primary_knowledge_source": "infores:text-mining-provider-targeted", "publications": ["PMC:5865770"], "tmkp_confidence_score": 0.99955505, "sentences": "Finally, the EPO + MPSS group exhibited the highest protein expression levels for AQP4 following reperfusion, and PKC inhibition partially but significantly inhibited this AQP4 upregulation (P<0.05;|NA", "tmkp_ids": ["tmkp:af9009dcefe29cbbe3eb6fb2e20da3baf717efcec8517fe84cb8cba683c6ad8c"], "knowledge_level": "not_provided", "agent_type": "text_mining_agent", "qualified_predicate": "biolink:causes", "object_aspect_qualifier": "activity_or_abundance", "object_direction_qualifier": "decreased", "original_subject": "CHEBI:6890", "original_object": "UniProtKB:Q02156"}
{"subject": "CHEBI:5186", "predicate": "biolink:affects", "object": "NCBIGene:9429", "primary_knowledge_source": "infores:text-mining-provider-targeted", "publications": ["PMID:32712543", "PMC:9229252"], "tmkp_confidence_score": 0.9996719199999999, "sentences": "The combination of the FUC and DOX decreased ABCC1, ABCG2, and ABCB1 expression.|NA|Besides, the treatment also reduces the expressions of transporter genes ABCC1, ABCG2 and ABCB1 when compared to Fx or DOX monotreatment.|NA", "tmkp_ids": ["tmkp:99a7ed4379d0ffec0fb70f2bc88564b694ac9e08f41fac825a77cdbe6bdc1d55", "tmkp:33eadf5eb3a8ccbcc40ce00f5117935f23442f8cafc83dadb48294e0f13b6781"], "knowledge_level": "not_provided", "agent_type": "text_mining_agent", "qualified_predicate": "biolink:causes", "object_aspect_qualifier": "activity_or_abundance", "object_direction_qualifier": "decreased", "original_subject": "DRUGBANK:DB15462", "original_object": "UniProtKB:Q9UNQ0"}
{"subject": "CHEBI:16236", "predicate": "biolink:affects", "object": "NCBIGene:5213", "primary_knowledge_source": "infores:text-mining-provider-targeted", "publications": ["PMC:7310068"], "tmkp_confidence_score": 0.97703606, "sentences": "Similar effect but with less increases of PFK1 mRNA level were found in high glucose, ethanol, and heat stresses, and that for PFK2 was uniquely observed in heat stress with 39% increase; more increases (111% and 58%, respectively) for TDH1 were displayed in high glucose and ethanol stresses.|NA", "tmkp_ids": ["tmkp:739965deebed410560cb80c1c5667011cfb98c94e2fa40de7047742c572614dc", "tmkp:7e50531e6cfadbef5100746ccea7a0c29c97cd0a0271623c721dff1b7159f9fb"], "knowledge_level": "not_provided", "agent_type": "text_mining_agent", "qualified_predicate": "biolink:causes", "object_aspect_qualifier": "activity_or_abundance", "object_direction_qualifier": "increased", "original_subject": "DRUGBANK:DB00898", "original_object": "UniProtKB:P08237"}
{"subject": "CHEBI:59695", "predicate": "biolink:contributes_to", "object": "MONDO:0000437", "primary_knowledge_source": "infores:text-mining-provider-targeted", "publications": ["PMC:4418056"], "tmkp_confidence_score": 0.99930584, "sentences": "However, the clinical uses of cyproheptadine hydrochloride is limited by its side effects such as somnolence, excitation, hallucinations, ataxia, tachycardia, muscle twitching, occasionally gastric pain, dry mucous surfaces, mydriasis, and rubeosis of the face (Von M?hlendahl and Krienke, 1978).|NA", "tmkp_ids": ["tmkp:8f2a89141c8ca9225029c228d841cc271552f0a2bf001c0f95d71e07b92de000"], "knowledge_level": "not_provided", "agent_type": "text_mining_agent", "original_subject": "CHEBI:59695", "original_object": "HP:0001251"}
{"subject": "UMLS:C0010590", "predicate": "biolink:contributes_to", "object": "MONDO:0001673", "primary_knowledge_source": "infores:text-mining-provider-targeted", "publications": ["PMC:3415581"], "tmkp_confidence_score": 0.6155770838705931, "sentences": "The most common AEs were pains associated with arthritis (7 reports for one participant), cough (3 reports for 3 participants), and cold symptoms (2 reports for 2 participants), vomiting/diarrhea (1 report), and high blood pressure (1 report), but these were not likely related to D-cycloserine or placebo administration.|NA", "tmkp_ids": ["tmkp:6a59b7fa3bba24542e4384d96a75eb4daf1b170debcf39d6810dcf34cc883e19"], "knowledge_level": "not_provided", "agent_type": "text_mining_agent", "original_subject": "DRUGBANK:DB00260", "original_object": "MONDO:0001673"}
{"subject": "UMLS:C3827082", "predicate": "biolink:contributes_to", "object": "HP:0012398", "primary_knowledge_source": "infores:text-mining-provider-targeted", "publications": ["PMC:6366347", "PMC:5742464"], "tmkp_confidence_score": 1.2117030438656968, "sentences": "Pruritus (9.6%), peripheral edema (8.6%), and rash (8.4%) were common skin adverse effects in patients treated with atezolizumab in this analysis.|NA|In addition, pyrexia and peripheral edema were reported in the atezolizumab- and durvalumab-treated groups, respectively.|NA", "tmkp_ids": ["tmkp:66424bc5dbe442a7e5ba2f13e8d814a1c613ca5b16a96cd0c9635d613c39ff68", "tmkp:7f463784a65edee90b1e155d9840a4911ee42c79a008b33fea6f292b250f64f8"], "knowledge_level": "not_provided", "agent_type": "text_mining_agent", "original_subject": "DRUGBANK:DB11595", "original_object": "HP:0012398"}
{"subject": "CHEBI:194425", "predicate": "biolink:treats_or_applied_or_studied_to_treat", "object": "MONDO:0015459", "primary_knowledge_source": "infores:text-mining-provider-targeted", "publications": ["PMC:9169397", "PMC:5311839", "PMC:8993549", "PMC:5311839", "PMC:5311839"], "tmkp_confidence_score": 0.9400328652523186, "sentences": "Clinical studies, such as ChiCTR1900021536 and ChiCTR-IIR-17013112, are ongoing and aim to further assess the benefits and risks of lobaplatin for NPC and verify the value of these treatment strategies.|NA|However, randomized controlled studies are needed to compare the efficacy of lobaplatin and other reagents as a first-line systemic treatment for LA-NPC.|NA|Lobaplatin induces pyroptosis through regulating cIAP1/2, ripoptosome and ROS in nasopharyngeal carcinoma|NA|Randomized controlled trials of lobaplatin in patients with LA-NPC are warranted.|NA|However, the safety and efficacy of lobaplatin as a first-line regimen in patients with LA-NPC are undetermined.|NA", "tmkp_ids": ["tmkp:492129a1fbd47695d750f137b888f79c324b7cb485e292ffd6bcb9212a1c42d2", "tmkp:a6879753a3fe5d2b18f74c9efe6d8aae2fd7e9bfbbd74548cf2a9bb1a7e203b2", "tmkp:91d159047f90fdbf5c70c8f9e3f31dd9f3fc4600956d87efe3034a850469d045", "tmkp:ba6bdd69aa84a92952cc7cb83b564ca5d3e6962836a408c31be454801ae90072", "tmkp:a72304902b85483fafe774332da11f5e1097bf84c5d09c3e5bd5463e1d3d5a11"], "knowledge_level": "not_provided", "agent_type": "text_mining_agent", "original_subject": "DRUGBANK:DB13049", "original_object": "MONDO:0015459"}
{"subject": "DRUGBANK:DB05794", "predicate": "biolink:treats_or_applied_or_studied_to_treat", "object": "MONDO:0016356", "primary_knowledge_source": "infores:text-mining-provider-targeted", "publications": ["PMC:2725229"], "tmkp_confidence_score": 1.1270662305123254, "sentences": "Subjects with dcSSc were enrolled in this clinical trial evaluating the safety, efficacy and dose-response effect of continuous subcutaneously infused recombinant human relaxin.|NA", "tmkp_ids": ["tmkp:6cb84e3544b6708389712275a07377c874ab01f5c3dcd2a8f04c187e7021afda"], "knowledge_level": "not_provided", "agent_type": "text_mining_agent", "original_subject": "DRUGBANK:DB05794", "original_object": "MONDO:0016356"}
{"subject": "UNII:781E2AXH0K", "predicate": "biolink:contributes_to", "object": "HP:0003326", "primary_knowledge_source": "infores:text-mining-provider-targeted", "publications": ["PMC:9067419"], "tmkp_confidence_score": 1.3017308763792057, "sentences": "Leg cramps, myalgia, and arthralgia are reported among IV ferric gluconate side-effects, but rhabdomyolysis is not .|NA", "tmkp_ids": ["tmkp:6e458a38e13b07a1e5b2e5098c7f938350cbed120eb31f7640982be13415846e"], "knowledge_level": "not_provided", "agent_type": "text_mining_agent", "original_subject": "DRUGBANK:DB14488", "original_object": "HP:0003326"}
{"subject": "UMLS:C3490795", "predicate": "biolink:treats_or_applied_or_studied_to_treat", "object": "HP:0000924", "primary_knowledge_source": "infores:text-mining-provider-targeted", "publications": ["PMC:8518624"], "tmkp_confidence_score": 0.8925023882421638, "sentences": "In clinical studies in infants and children, treatment with asfotase alfa reduced levels of accumulated TNSALP substrates and improved bone mineralization, growth, mobility, and survival and reduced skeletal abnormalities and respiratory symptoms, with benefits sustained for up to 7 years.|NA", "tmkp_ids": ["tmkp:b1c8ab1c30c39fec359f2c9054a8743957b1a717e0919e18ac4934258c0724dc"], "knowledge_level": "not_provided", "agent_type": "text_mining_agent", "original_subject": "DRUGBANK:DB09105", "original_object": "HP:0000924"}
{"subject": "CHEBI:16236", "predicate": "biolink:contributes_to", "object": "HP:0006846", "primary_knowledge_source": "infores:text-mining-provider-targeted", "publications": ["PMC:3525059", "PMC:6177108", "PMC:7208054"], "tmkp_confidence_score": 0.9805362999999999, "sentences": "Alcohol or toxic substances may also act as triggers of acute encephalopathy, but our information was not sufficient to explore this association.|NA|A 72-year-old African American male patient with a history of alcohol abuse presented with acute encephalopathy and failure to thrive (FTT) with unintentional weight loss.|NA|67 year old with history of alcohol abuse with 17.8 x 8.8 cm mass in the left hepatic lobe presented with acute encephalopathy and calcium of 14.4 mg/dl.|NA", "tmkp_ids": ["tmkp:17ba79be6f443f1cb0f7a83336c2bdb7449b0184dabd7312f88b3950cf1c8d70", "tmkp:4a7df87bbb98b85fa0ab289b0ce200c8ff0a457f3c0a567b74bec578350f777a", "tmkp:eb70b0ea62c9f6934a13c2c60791ac01f367b218de91a7e5bbbe695cd0151a17"], "knowledge_level": "not_provided", "agent_type": "text_mining_agent", "original_subject": "DRUGBANK:DB00898", "original_object": "HP:0006846"}
{"subject": "NCBIGene:213", "predicate": "biolink:treats_or_applied_or_studied_to_treat", "object": "MONDO:0005096", "primary_knowledge_source": "infores:text-mining-provider-targeted", "publications": ["PMC:9141473"], "tmkp_confidence_score": 0.5612787669627537, "sentences": "A near infrared light-triggered human serum albumin drug delivery system with coordination bonding of indocyanine green and cisplatin for targeting photochemistry therapy against oral squamous cell cancer|NA", "tmkp_ids": ["tmkp:4745d592e799e787d4efe5263afbff07470a6b0c56edd8ec3611d1f01254cc4e"], "knowledge_level": "not_provided", "agent_type": "text_mining_agent", "original_subject": "DRUGBANK:DB00062", "original_object": "MONDO:0005096"}
{"subject": "CHEBI:16236", "predicate": "biolink:treats_or_applied_or_studied_to_treat", "object": "HP:0002902", "primary_knowledge_source": "infores:text-mining-provider-targeted", "publications": ["PMC:2504060", "PMC:8639540"], "tmkp_confidence_score": 1.2335098950872412, "sentences": "The therapeutic potential of ethanol in the management of hyponatremia, however, is unacceptable because of the multiple medical complications associated with its use.|NA", "tmkp_ids": ["tmkp:5a1182928bdc3d1eaf90dafc8d39c6f0d74789a461427bcf6c4b6fd7bf404268", "tmkp:778afa3bdfb804d2c0dfa636406254faf61aaf55ce745375025220dd1eb48b3b", "tmkp:8bfdc0d04fc88d10505efda6fb89a91f3a512d886a9103ceba0f52574b99b55c"], "knowledge_level": "not_provided", "agent_type": "text_mining_agent", "original_subject": "CHEBI:16236", "original_object": "HP:0002902"}
{"subject": "DRUGBANK:DB09446", "predicate": "biolink:affects", "object": "NCBIGene:3552", "primary_knowledge_source": "infores:text-mining-provider-targeted", "publications": ["PMID:3041642"], "tmkp_confidence_score": 0.99968684, "sentences": "In contrast, after 6 weeks of feeding, Kupffer cells from both the FO and the SO groups released less IL-1 and tumor necrosis factor when triggered by lipopolysaccharide than Kupffer's cells from animals fed the control diet that contained CO.|NA", "tmkp_ids": ["tmkp:8dec53d7e69209f6456e0e7908385cec894c39793ce409220518d78b719a6b4c"], "knowledge_level": "not_provided", "agent_type": "text_mining_agent", "qualified_predicate": "biolink:causes", "object_aspect_qualifier": "activity_or_abundance", "object_direction_qualifier": "decreased", "original_subject": "DRUGBANK:DB09446", "original_object": "UniProtKB:P01583"}
{"subject": "CHEBI:16236", "predicate": "biolink:contributes_to", "object": "MONDO:0005098", "primary_knowledge_source": "infores:text-mining-provider-targeted", "publications": ["PMC:3676342", "PMC:7667520", "PMC:8927699", "PMC:8387962"], "tmkp_confidence_score": 0.6174326831279786, "sentences": "There is emerging evidence that episodic consumption of high amounts of alcohol (binge drinking) is associated with high risk of coronary heart disease, stroke and metabolic syndrome.|NA|Stroke has been associated with various risk factors, such as lifestyle-related eating habits, tobacco and/or alcohol use, and decreased physical activity, underlying comorbidities, such as obesity, hypertension, dyslipidemia, diabetes mellitus type 2, lung and kidney failures, etc., as well as exposure to environmental pollutants.|NA|Common risk factors for stroke include hypertension, dyslipidemia, diabetes, smoking, alcohol, and low fruit and vegetable diet.|NA|Exclusion criteria were:1) excessive alcohol use (>140g/week for men and >70 g/week for women); 2) previously diagnosed hepatitis, cirrhosis or other chronic liver diseases (e.g., autoimmune liver disease, primary sclerosing cholangitis, drug-induced liver disease); 3) history of thyroidectomy, overt thyroid dysfunction, autoimmune thyroiditis, or thyroid tumor; 4) previous or current use thyroid hormone or anti?thyroid drugs, or drugs that cause a fatty liver and/or liver fibrosis; 5) previously diagnosed chronic kidney disease, stroke, acute coronary syndrome, malignant tumors.|NA", "tmkp_ids": ["tmkp:6c2eb250dabfe44e2e585f1b51c40e23ad1d8094f10da55d47ccc8059198388e", "tmkp:56023ec0eecbef8e39503766dd8c66bea02a55227d1a12b4c95ec3b38a6cf346", "tmkp:fe0331b0d39910353a0b1c1b54a40e8c90fb9d7149e765a4d74808e0b719c13d", "tmkp:f0a3b7084a22ec14f5c060f2680a171b9c1f74ec2a7072d0050a479fe7afc3d2"], "knowledge_level": "not_provided", "agent_type": "text_mining_agent", "original_subject": "DRUGBANK:DB00898", "original_object": "MONDO:0005098"}
{"subject": "UNII:7CVR7L4A2D", "predicate": "biolink:treats_or_applied_or_studied_to_treat", "object": "MONDO:0015784", "primary_knowledge_source": "infores:text-mining-provider-targeted", "publications": ["PMC:4683806"], "tmkp_confidence_score": 0.9994143, "sentences": "Caralluma fimbriata extract against a placebo of maltodextrin/cabbage leaf in children and adolescent participants with Prader-Willi syndrome (PWS) (n = 15)|NA", "tmkp_ids": ["tmkp:aecdb4efd2b44d846db9b4a7f420486f601d056a6c5d851edfdb8733a95bcd72"], "knowledge_level": "not_provided", "agent_type": "text_mining_agent", "original_subject": "DRUGBANK:DB12583", "original_object": "MONDO:0015784"}
{"subject": "UNII:90G53638ZD", "predicate": "biolink:treats_or_applied_or_studied_to_treat", "object": "HP:0002788", "primary_knowledge_source": "infores:text-mining-provider-targeted", "publications": ["PMC:8903879"], "tmkp_confidence_score": 0.9994822, "sentences": "Amongst other indications, including immunodeficiencies, AZB has proven therapeutic benefits in the treatment of upper respiratory tract infections.|NA", "tmkp_ids": ["tmkp:5f99fc744cf0db7802f356ed8b1662b9577059ef514c62633d344e9b3823d79a"], "knowledge_level": "not_provided", "agent_type": "text_mining_agent", "original_subject": "DRUGBANK:DB15689", "original_object": "HP:0002788"}
{"subject": "MONDO:0008315", "predicate": "biolink:treats_or_applied_or_studied_to_treat", "object": "CHEBI:59809", "primary_knowledge_source": "infores:text-mining-provider-targeted", "publications": ["PMC:7449903", "PMC:8560597"], "tmkp_confidence_score": 0.6171503292608909, "sentences": "Although this study provides a promising concept for the treatment of prostate cancer, the efficacy of CaO2@HMSNs-PAA is not as ideal as some clinical antitumor drugs, such as docetaxel which has been widely used as one of the most potent antitumor therapy for prostate cancer with a significant clinical benefit in survival.|NA|Schematic diagram of AS1411@MPDA?DTX?mediated synergistic therapy for prostate cancer and the underlying mechanism.|NA", "tmkp_ids": ["tmkp:4e269386b61ed9bb56f4701813246a4c72ed1d34eb720203e93387c6a771eb26", "tmkp:b3eda266e1cca6b29b3ab66c9eacd304725c998f2581313f902d0411bd0fc650"], "knowledge_level": "not_provided", "agent_type": "text_mining_agent", "original_subject": "MONDO:0008315", "original_object": "DRUGBANK:DB01248"}
{"subject": "NCBIGene:1956", "predicate": "biolink:affects", "object": "DRUGBANK:DB15037", "primary_knowledge_source": "infores:text-mining-provider-targeted", "publications": ["PMC:6242943"], "tmkp_confidence_score": 0.9996675, "sentences": "Treatment of ELTN+FDTN@PEG-PLA led to decreased expression level of p-EGFR and p-STAT3 than free drugs (ELTN+FDTN), which might be attributed to the long circulation and tumor targeting effect enabled by the NPs.|NA", "tmkp_ids": ["tmkp:8ce93ca45350b0f346082a4a51bdbe4fd049daea6e8da215b09457e4b51d5cd1"], "knowledge_level": "not_provided", "agent_type": "text_mining_agent", "qualified_predicate": "biolink:causes", "object_aspect_qualifier": "activity_or_abundance", "object_direction_qualifier": "decreased", "original_subject": "UniProtKB:P00533", "original_object": "DRUGBANK:DB15037"}
{"subject": "CHEBI:136195", "predicate": "biolink:contributes_to", "object": "MONDO:0000831", "primary_knowledge_source": "infores:text-mining-provider-targeted", "publications": ["PMC:5360178"], "tmkp_confidence_score": 0.9990772, "sentences": "Intravital thrombosis studies demonstrated that CEP-phosphatidylethanolamine derivatives accelerate thrombosis in TLR2-dependent manner and TLR2 substantially contributes to accelerated thrombosis in mice in the settings of hyperlipidemia.|NA", "tmkp_ids": ["tmkp:8bd671085f55fbadd1ca43c2df743953598afdd98d5d90a1d8f8ee654813ec04"], "knowledge_level": "not_provided", "agent_type": "text_mining_agent", "original_subject": "CHEBI:136195", "original_object": "MONDO:0000831"}
{"subject": "CHEBI:15358", "predicate": "biolink:contributes_to", "object": "HP:0000969", "primary_knowledge_source": "infores:text-mining-provider-targeted", "publications": ["PMC:5404986", "PMC:7691956"], "tmkp_confidence_score": 0.7929201186971693, "sentences": "Histones were also greatly increased in the circulation of patients with trauma-induced lung injury, and histone infusion in mice increased cytokine production, endothelial damage, coagulation, PMN infiltration, and edema; the mechanism involved plasma membrane binding and calcium influx.|NA|In the H&E staining, the result of which was consistent with that of the vascular permeability assay, the lungs of histone-infused mice showed congestion and edema and were concomitant with neutrophil infiltration in the alveolar capillaries, which was attenuated in the ADSCs+histones group (Fig.?1d).|NA", "tmkp_ids": ["tmkp:1ca2b717ab9514eec1c2c825843b5525e7fa4a764d926eba5b095dd03ea4b869", "tmkp:9271916754b33a0b148d1efc801b236da7ff46f0e4c2ea7741f30fb3a0a8040e"], "knowledge_level": "not_provided", "agent_type": "text_mining_agent", "original_subject": "CHEBI:15358", "original_object": "HP:0000969"}
{"subject": "NCBIGene:3458", "predicate": "biolink:affects", "object": "CHEBI:28544", "primary_knowledge_source": "infores:text-mining-provider-targeted", "publications": ["PMC:8020625"], "tmkp_confidence_score": 0.99916315, "sentences": "CbP/siPD-L1@Dig led to the highest secretion of IFN-? by inguinal lymph node cells in comparison to PBS and other treatment groups, indicating the presenting of antigen fragments and activation of lymphoid cells by DCs (Fig. S24b).|NA", "tmkp_ids": ["tmkp:d175bbe651f699810791abeecc05685859e36200a4c43b7bf657852f14209e1b"], "knowledge_level": "not_provided", "agent_type": "text_mining_agent", "qualified_predicate": "biolink:causes", "object_aspect_qualifier": "activity_or_abundance", "object_direction_qualifier": "increased", "original_subject": "UniProtKB:P01579", "original_object": "DRUGBANK:DB01396"}
{"subject": "NCBIGene:213", "predicate": "biolink:contributes_to", "object": "MONDO:0008170", "primary_knowledge_source": "infores:text-mining-provider-targeted", "publications": ["PMC:8296848"], "tmkp_confidence_score": 0.561810394012574, "sentences": "Ovarian cancer is associated with high serum calcium and low serum albumin in clinical and epidemiologic studies.|NA", "tmkp_ids": ["tmkp:c4ee67045d200d8baa72b63a6e7d8ead2f18d2c0d7a7bd1b0a335f1178bf4c17"], "knowledge_level": "not_provided", "agent_type": "text_mining_agent", "original_subject": "DRUGBANK:DB00062", "original_object": "MONDO:0008170"}
{"subject": "NCBIGene:213", "predicate": "biolink:treats_or_applied_or_studied_to_treat", "object": "HP:0031274", "primary_knowledge_source": "infores:text-mining-provider-targeted", "publications": ["PMC:5978059"], "tmkp_confidence_score": 0.9506108926377896, "sentences": "Colloid solutions, such as dextrans, gelatine derivatives, hydroxy ethyl starches, and human albumin are large, oncotically active molecules that are used intravenously (i.v.) as volume plasma expanders in critical care medicine to retain water within the plasma space in patients with hypovolemic shock.|NA", "tmkp_ids": ["tmkp:2d55317c20f8eb8f2059c55f32e6374e386711e6f22731eaad2e8b313ab1ed10"], "knowledge_level": "not_provided", "agent_type": "text_mining_agent", "original_subject": "DRUGBANK:DB00062", "original_object": "HP:0031274"}
{"subject": "CHEBI:25681", "predicate": "biolink:treats_or_applied_or_studied_to_treat", "object": "HP:0001699", "primary_knowledge_source": "infores:text-mining-provider-targeted", "publications": ["PMC:2702061", "PMC:2993045", "PMC:3217043", "PMC:3261933", "PMC:3848082", "PMC:8955125"], "tmkp_confidence_score": 0.9127685, "sentences": "In the GISSI trial, the beneficial effect on mortality (including sudden death) appeared early on after the start of supplementation; moreover, survival curves for the omega 3 fatty acid treatment diverged soon after randomisation.|NA", "tmkp_ids": ["tmkp:07a879a077f40f928f5f30ed443957fcb1fd0df0adb583d2fc539550c5a84918", "tmkp:0c33c35aad6d3b79e6ccb54b8cb8de285dfe4f316899ec7957602f5b4d7d1ea2", "tmkp:45ee50cbb8e3efa833e0871c9d12a4208cb21c08f7aa7c02188916d4dcfd380a", "tmkp:8fc02ab89751880bffd74af28b90d2588d760c0e6f616ad6287c47e7fd79ef59", "tmkp:9039a91034cd49cc928cc49fa8a6c6054ca5257571c1e0b691ba773741db7ea2", "tmkp:9c089f2e6ab208ed3fb1c03645b373d1c21ef4681d40955ac4c896a759d60bf7"], "knowledge_level": "not_provided", "agent_type": "text_mining_agent", "original_subject": "CHEBI:25681", "original_object": "HP:0001699"}
{"subject": "NCBIGene:213", "predicate": "biolink:contributes_to", "object": "HP:0003712", "primary_knowledge_source": "infores:text-mining-provider-targeted", "publications": ["PMC:5005829"], "tmkp_confidence_score": 0.9278884814444904, "sentences": "Another mechanism could be the activation of the phosphatidyl-inositol 3-kinase pathway by serum albumin (Jones et al.), leading to muscle hypertrophy (Lai et al.) and therefore an increase in muscle mass.|NA", "tmkp_ids": ["tmkp:3ef3d766fb7a5c08545395b62dd5bc06ede7d561e16b7601a8958a34377404af"], "knowledge_level": "not_provided", "agent_type": "text_mining_agent", "original_subject": "DRUGBANK:DB00062", "original_object": "HP:0003712"}
{"subject": "DRUGBANK:DB15656", "predicate": "biolink:treats_or_applied_or_studied_to_treat", "object": "MONDO:0005015", "primary_knowledge_source": "infores:text-mining-provider-targeted", "publications": ["PMC:9068501", "PMC:9068501", "PMC:9068501", "PMC:9068501", "PMC:8540274"], "tmkp_confidence_score": 0.99948038, "sentences": "Antibody levels in people with diabetes after one dose of the ChAdOx1 nCoV-19 (AZD1222) vaccine |NA|Antibody levels in people with diabetes after one dose of the ChAdOx1 nCoV-19 (AZD1222) vaccine |NA|Immune response data after a single dose of the AZD1222 vaccine in patients with diabetes are limited.|NA|This clinical study evaluated immune responses after the first dose of the AZD1222 vaccine in patients with diabetes.|NA|A 41-year-old man with diabetes under well medical control who works as an emergency physician received his first dose of AZD1222 2 weeks prior to the onset of symptoms.|NA", "tmkp_ids": ["tmkp:a62a7e0f040ba57ea8459c6e840dcb02038827908c798a40d46897d8ea0f56c4", "tmkp:11941715f101c24e7491ac9698eb4159f2af2fee71bc46b1760558f30a3b9b0d", "tmkp:e6150dec5bfc2205d45ba8d0a1643ee00f698d59e0f82050b8d2d76cdbcd6538", "tmkp:8750f0ea64cd729368413a508bcb4648411b08346640d43de56729ab8a08be18", "tmkp:23141b0581c90aa95afe31ced6d58eaaf9f8936fd5f3f6e528cbfb4f3d44c413"], "knowledge_level": "not_provided", "agent_type": "text_mining_agent", "original_subject": "DRUGBANK:DB15656", "original_object": "MONDO:0005015"}
{"subject": "DRUGBANK:DB15656", "predicate": "biolink:contributes_to", "object": "MONDO:0010528", "primary_knowledge_source": "infores:text-mining-provider-targeted", "publications": ["PMC:8904009"], "tmkp_confidence_score": 0.9426937, "sentences": "In severe AEs, the frequency of anosmia, acute kidney injury, acute liver damage, thrombocytopenic purpura, thrombocytopenia, neurological complications, and severe skin reactions was higher in AZD1222 than BNT162b2 (Figure?3, Table?5).|NA", "tmkp_ids": ["tmkp:1db964377254611343309e3fe38e0bc68af885a580c4517e041be520aa1dd51e"], "knowledge_level": "not_provided", "agent_type": "text_mining_agent", "original_subject": "DRUGBANK:DB15656", "original_object": "MONDO:0010528"}
{"subject": "MONDO:0004992", "predicate": "biolink:contributes_to", "object": "CHEBI:15551", "primary_knowledge_source": "infores:text-mining-provider-targeted", "publications": ["PMC:7432113"], "tmkp_confidence_score": 0.2473304249124015, "sentences": "The ability of GO@T hybrids to modulate the release of PGE2 in PC-3 and HREC was investigated as marker for the activation of inflammatory processes, which can have a crucial role both in carcinogenesis and cancer progression as well as in the angiogenic switch-on mechanism.|NA", "tmkp_ids": ["tmkp:4158a9e3223823ab0cb4dd7838f2c54ff5f875dc4d48571dda7eac37d99fa173", "tmkp:8844c4cb592ffce77d779803499e8bab1cd45d8b3ae22453f19ba4bc35d3932d"], "knowledge_level": "not_provided", "agent_type": "text_mining_agent", "original_subject": "MONDO:0004992", "original_object": "DRUGBANK:DB00917"}
{"subject": "DRUGBANK:DB09446", "predicate": "biolink:treats_or_applied_or_studied_to_treat", "object": "HP:0040270", "primary_knowledge_source": "infores:text-mining-provider-targeted", "publications": ["PMC:3674571"], "tmkp_confidence_score": 0.9695869, "sentences": "Although olive oil or safflower oil improved some indices of insulin signaling, the diet duration may not have been sufficient to reverse the impaired glucose tolerance and to improve vascular function.|NA", "tmkp_ids": ["tmkp:9d0f17e8c1cc76bacbf4fb0a806e328c1a4b26daeb7d240589337bfba36da375"], "knowledge_level": "not_provided", "agent_type": "text_mining_agent", "original_subject": "DRUGBANK:DB09446", "original_object": "HP:0040270"}
{"subject": "DRUGBANK:DB15656", "predicate": "biolink:contributes_to", "object": "HP:0030528", "primary_knowledge_source": "infores:text-mining-provider-targeted", "publications": ["PMC:8875181"], "tmkp_confidence_score": 0.99786264, "sentences": "B?hler et al. reported on a 27-year-old female with no past medical history who developed flu-like symptoms followed by a paracentral scotoma OS two days after receiving the AZD1222 vaccine.|NA", "tmkp_ids": ["tmkp:371e6734233ebbe65957155a53fb6192cec3124256295201fbc7d1fa5e2fe179"], "knowledge_level": "not_provided", "agent_type": "text_mining_agent", "original_subject": "DRUGBANK:DB15656", "original_object": "HP:0030528"}
{"subject": "MONDO:0004992", "predicate": "biolink:treats_or_applied_or_studied_to_treat", "object": "UMLS:C0041249", "primary_knowledge_source": "infores:text-mining-provider-targeted", "publications": ["PMC:8586589", "PMC:8586589", "PMC:8586589"], "tmkp_confidence_score": 0.2342104302790704, "sentences": "Taken collectively, LJ@Trp-NPs elicit their anticancer effect by blocking the entry of amino acids into cancer cells and consequently interfering with cellular metabolism and signaling pathways.|NA|LJ@Trp-NPs were designed to interfere with amino acid entry into cancer cells with consequent detrimental changes in amino acid metabolism and associated cellular signaling and biological processes.|NA|This mode of anticancer effect of LJ@Trp-NPs by limiting the supply of amino acids to cancer cells is likely to amplify the anticancer efficacy of lapatinib and possibly deter development of resistance to lapatinib.|NA", "tmkp_ids": ["tmkp:ccf3bd79584eaf8dbe56f76395a2668c5e1f3cd04327871f066f9ba04c713fd0", "tmkp:148844e880798e04e24361d895167c1b7f59777e7373ce83039aa521d6855e80", "tmkp:84e3877bb28df7bf837d02b20bd82acb7f91b010167dd7a03894eb2b5f362f16"], "knowledge_level": "not_provided", "agent_type": "text_mining_agent", "original_subject": "MONDO:0004992", "original_object": "DRUGBANK:DB00150"}
{"subject": "HP:0001510", "predicate": "biolink:contributes_to", "object": "CHEBI:27899", "primary_knowledge_source": "infores:text-mining-provider-targeted", "publications": ["PMC:6376191"], "tmkp_confidence_score": 0.6529963641100585, "sentences": "As shown in Figure 9C-D and Figure S18A, C, HT@CDDP induced a remarkable tumor growth delay and, 13 days after treatment, the tumor size (5.70 ? 1.14 mm3) was reduced by 82.78% compared with the untreated control (33.11 ? 4.63 mm3).|NA", "tmkp_ids": ["tmkp:13577809435a7de92b00b14fc5a14ff8c010a136e900860b78ae02928a9088ea"], "knowledge_level": "not_provided", "agent_type": "text_mining_agent", "original_subject": "HP:0001510", "original_object": "DRUGBANK:DB00515"}
{"subject": "MONDO:0002771", "predicate": "biolink:contributes_to", "object": "UMLS:C0005740", "primary_knowledge_source": "infores:text-mining-provider-targeted", "publications": ["PMC:9216512", "PMC:9216512", "PMC:9216512"], "tmkp_confidence_score": 0.7726991358851115, "sentences": "siIL11@PPGC NPs mitigate bleomycin-induced pulmonary fibrosis|NA|Inhalation of siIL11@PPGC NPs restores the pulmonary function in the mouse model of bleomycin-induced pulmonary fibrosis.|NA|Inhaled siIL11@PPGC NPs inhibit fibroblast activation and ECM production in the mouse model of bleomycin-induced pulmonary fibrosis.|NA", "tmkp_ids": ["tmkp:b8912185ebff2fc55c48ddd3bb91b32312272f256b3ba3087342582974ebfea4", "tmkp:78d960c43593a81792c361d16f360bdb8fc50a085c3297351f7e2d72675045ed", "tmkp:853d0a215b0f9905a36e383fdb2b8005b51c7230fe3741bc0b47a75e5d27c143"], "knowledge_level": "not_provided", "agent_type": "text_mining_agent", "original_subject": "MONDO:0002771", "original_object": "DRUGBANK:DB00290"}
{"subject": "MONDO:0005178", "predicate": "biolink:treats_or_applied_or_studied_to_treat", "object": "CHEBI:4462", "primary_knowledge_source": "infores:text-mining-provider-targeted", "publications": ["PMC:9253376", "PMC:9253376"], "tmkp_confidence_score": 0.9991653, "sentences": "Therefore, the neutrophil erythrocyte hybrid membranes camouflaged hollow copper sulfide nanoparticles (D-CuS@NR NPs) loading dexamethasone sodium phosphate (Dexp) were designed by Xue et al. for the treatment of OA.|NA|Therefore, the neutrophil erythrocyte hybrid membranes camouflaged hollow copper sulfide nanoparticles (D-CuS@NR NPs) loading dexamethasone sodium phosphate (Dexp) were designed by Xue et al. for the treatment of OA.|NA", "tmkp_ids": ["tmkp:e8638fbe566f746cc709709cad2ea090f65a451d2ded9aafb1013cf71596b222", "tmkp:9ec5593ead139e7be3ca2363194f543bbe548d651c9ebad4a73ebdc7357310a9"], "knowledge_level": "not_provided", "agent_type": "text_mining_agent", "original_subject": "MONDO:0005178", "original_object": "CHEBI:4462"}
{"subject": "HP:0001945", "predicate": "biolink:treats_or_applied_or_studied_to_treat", "object": "CHEBI:28748", "primary_knowledge_source": "infores:text-mining-provider-targeted", "publications": ["PMC:7828119", "PMC:9323998"], "tmkp_confidence_score": 0.6517418423327936, "sentences": "A photothermal material using Au@m-SiO2 nanocube-loaded doxorubicin (DOX) as the chemotherapeutic drug grafted with Mn-CDs shows multiple applications for hyperthermia, chemotherapy, and oxygen-evolving in situ PDT under bi-irradiation at 635 and 808 nm.|NA|Similarly, Yu et al. developed a H2O2/NIR-responsive nanoplatform (MnPB @polypyrrole [MnPB@PPy]) to load Doxorubicin (DOX) by making MnPB@PPy core?shell-structured nanocarrier for MRI-guided co-chemotherapy/hyperthermia.|NA|A photothermal material using Au@m-SiO2 nanocube-loaded doxorubicin (DOX) as the chemotherapeutic drug grafted with Mn-CDs shows multiple applications for hyperthermia, chemotherapy, and oxygen-evolving in situ PDT under bi-irradiation at 635 and 808 nm.|NA", "tmkp_ids": ["tmkp:00c9801aa27520267ef537ff697b49efd4fb3bbd481bfe2accd1ea3a006268c3", "tmkp:152dc18585b4858139a8c8ffe127bdb7ef97682589f90be966c5934fb6cb0e2f", "tmkp:5565eec35abae850ebfea2e541d06ed82ff04e1a8f63047de8d8de5a22691b89", "tmkp:975c307e877504610e7b1bd232333627c22b8ec0eb39c573408fbb3a2ba9f8e0"], "knowledge_level": "not_provided", "agent_type": "text_mining_agent", "original_subject": "HP:0001945", "original_object": "DRUGBANK:DB00997"}
{"subject": "NCBIGene:4288", "predicate": "biolink:affects", "object": "CHEBI:31696", "primary_knowledge_source": "infores:text-mining-provider-targeted", "publications": ["PMC:9120472"], "tmkp_confidence_score": 0.999647, "sentences": "Meanwhile, Cal@MPs and Cal/ICG@MPs significantly inhibited the ratios of Ki67-positive proliferative CAFs (Supplementary Fig.?18d).|NA", "tmkp_ids": ["tmkp:1943c62488c59c7ca7592d59b13e048df2778f774f8031845706843541be5cf6"], "knowledge_level": "not_provided", "agent_type": "text_mining_agent", "qualified_predicate": "biolink:causes", "object_aspect_qualifier": "activity_or_abundance", "object_direction_qualifier": "decreased", "original_subject": "UniProtKB:P46013", "original_object": "DRUGBANK:DB16024"}
{"subject": "MONDO:0021063", "predicate": "biolink:treats_or_applied_or_studied_to_treat", "object": "CHEBI:5186", "primary_knowledge_source": "infores:text-mining-provider-targeted", "publications": ["PMC:9146768"], "tmkp_confidence_score": 0.7473778955137469, "sentences": "A recent study showed that fucoxanthin@polyvinylpyrrolidone nanoparticles effectively delivered fucoxanthin into human colon cancer cells in vitro, confirming a new and targeted therapeutic approach.|NA", "tmkp_ids": ["tmkp:b5acd8d047d68386ac19de94d88617c60764fbad85549da880dee2b50fa0a68d"], "knowledge_level": "not_provided", "agent_type": "text_mining_agent", "original_subject": "MONDO:0021063", "original_object": "DRUGBANK:DB15462"}
{"subject": "MONDO:0004992", "predicate": "biolink:treats_or_applied_or_studied_to_treat", "object": "NCBIGene:213", "primary_knowledge_source": "infores:text-mining-provider-targeted", "publications": ["PMC:5602453", "PMC:9053164"], "tmkp_confidence_score": 0.2376184596187509, "sentences": "Compared to other singular treatment groups, P@-Gem-HSA-NPs (L+) showed a highly synergistic effect in destructing cancer cells by in vitro of combined PDT and chemotherapy (P<0.05).|NA|The greater therapeutic efficiency of CTAC@MSNs-HSA is mainly attributed to the presence of HSA, which increase the cell uptake of nanomaterials and improve their biocompatibility, thus provide the prolonged cytotoxicity of nanomaterials against cancer cells.|NA", "tmkp_ids": ["tmkp:1acfe86ef33199d48c9ac06fad51f1920786bbdfb9cd770915c4e40870282a08", "tmkp:5272965de4ad6fe3443e0d85771f30656c98ea423b21852c97ea5ea3111ee866"], "knowledge_level": "not_provided", "agent_type": "text_mining_agent", "original_subject": "MONDO:0004992", "original_object": "DRUGBANK:DB00062"}
{"subject": "HP:0001945", "predicate": "biolink:treats_or_applied_or_studied_to_treat", "object": "NCBIGene:213", "primary_knowledge_source": "infores:text-mining-provider-targeted", "publications": ["PMC:7755349"], "tmkp_confidence_score": 0.6184915950211146, "sentences": "Treatment using SPIO@PSS/CDDP/HSA?MTX NPs and RF irradiation allows the CDDP-based chemotherapeutic drug to act synergistically with hyperthermia to provide a profound anticancer effect.|NA", "tmkp_ids": ["tmkp:b2acb3d5f7152b54b1f9fd2acb37195233305b3ec8bc7ec46beef89fa0680ca0"], "knowledge_level": "not_provided", "agent_type": "text_mining_agent", "original_subject": "HP:0001945", "original_object": "DRUGBANK:DB00062"}
{"subject": "HP:0001945", "predicate": "biolink:treats_or_applied_or_studied_to_treat", "object": "CHEBI:184335", "primary_knowledge_source": "infores:text-mining-provider-targeted", "publications": ["PMC:6857040"], "tmkp_confidence_score": 0.8347018459598716, "sentences": "Overall, the good stability of DOX-DiR@cerasome (ABC), together with its rapidly accelerated drug release under hyperthermia, made it possible for effective anticancer drug delivery with reduced undesirable premature leakage and on-demand site specific release, thus enhancing chemo-photothermal combination therapy.|NA", "tmkp_ids": ["tmkp:867e621b6100eeb3be07028f3fc18e1bf793b914f4815f7e8ff8900748e1dee7"], "knowledge_level": "not_provided", "agent_type": "text_mining_agent", "original_subject": "HP:0001945", "original_object": "DRUGBANK:DB15925"}